Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: A nationwide study - 26/11/21
, Caroline Sindet-Pedersen, MSc, PhD a, b, Gunnar H. Gislason, MD, PhD a, b, c, Christian Torp-Pedersen, MD, DMSc d, e, Kristian H. Kragholm, MD, PhD e, Camilla Lundahl, MB e, Emil L. Fosbøl, MD, PhD f, Jawad H. Butt, MD f, Lars Køber, MD, DMSc f, Lars Søndergaard, MD, DMSc f, Jonas B. Olesen, MD, PhD aRésumé |
Aim |
To investigate trends in the utilization of transcatheter aortic valve replacement (TAVR) and changes in the characteristics of patients undergoing first-time TAVR.
Methods |
Using Danish nationwide registers, we included all patients undergoing TAVR between 2008 and 2020. To compare patient characteristics, the study population was stratified according to calendar year of procedure: 2008-2010, 2011-2013, 2014-2016, and 2017-2020.
Results |
We identified 6,097 patients undergoing TAVR with year-by-year increases in TAVR penetration rate. Over time, the age of the patients remained stable (2008-2010: median age 82 year [interquartile range (IQR): 77-86] vs 2017-2020: median age 81 years [IQR: 77-85]). Moreover, there was an increase in male patients (2008-2010: 49.9% vs 2017-2020: 57.4%) and patients with diabetes (2008-2010: 14.2% vs 2017-2020: 19.2%). Conversely, a history of stroke (2008-2010: 15.8% vs 2017-2020: 13.1%), previous myocardial infarction (2008-2010: 22.4% vs 2017-2020: 10.0%), heart failure (2008-2010: 40.5% vs 2017-2020: 25.2%), and peripheral artery disease (2008-2010: 14.8% vs 2017-2020: 10.4) decreased among patients.
Conclusions |
TAVR utilization increased markedly in the years 2008-2020. Patients undergoing TAVR had less comorbidity over time while age remained stable. Thus, despite expanding to patients at lower surgical risk, TAVR is still offered mainly to older patients.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Graphical abstract
Plan
Vol 243
P. 140-146 - janvier 2022 Retour au numéro
Article précédent
- Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease
- Tyson S. Burnham, Heidi T. May, Tami L. Bair, Jeffrey A. Anderson, Brian G. Crandall, Michael J. Cutler, John D. Day, Roger A. Freedman, Kirk U. Knowlton, Joseph B. Muhlestein, Leenhapong Navaravong, Ravi A. Ranjan, Benjamin A. Steinberg, T. Jared Bunch
- Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial
- Matthew A Cavender, Michelle L. O'Donoghue, Antonio Abbate, Philip Aylward, Keith AA Fox, Ruchira X Glaser, Jeong-Gun Park, Jose Lopez-Sendon, Ph Gabriele Steg, Marc S Sabatine, David A Morrow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?